Table 2 Patient demographic, clinical and treatment characteristics, National Cancer Data Base 2010–2017 Chemotherapy alone vs Chemotherapy followed by Surgery, Patients ≥ 70 with cT1–3/cN0–3, Triple Negative or HER2 Positive invasive breast cancer treated with surgery and/or chemotherapy (N = 367)
Value or no. of patients (Column %) | |||
|---|---|---|---|
Chemotherapy alone (n = 81) | Chemotherapy followed by surgery (n = 286) | p-Value | |
Age (median, range), years | 76 (71–90) | 75 (71–90) | 0.002 |
Clinical T Stage (cT) | 0.64 | ||
T1 | 15 (18.52%) | 45 (15.73%) | |
T2 | 51 (62.96%) | 196 (68.53%) | |
T3 | 15 (18.52%) | 45 (15.73%) | |
Clinical N Stage (cN) | 0.007 | ||
N0 | 30 (37.04%) | 166 (58.04%) | |
N1 | 44 (54.32%) | 98 (34.27%) | |
N2 | 5 (6.17%) | 13 (4.55%) | |
N3 | 2 (2.47%) | 9 (3.15%) | |
Year of diagnosis | 0.87 | ||
2010 | 1 (1.23%) | 10 (3.5%) | |
2011 | 3 (3.7%) | 17 (5.94%) | |
2012 | 6 (7.41%) | 18 (6.29%) | |
2013 | 6 (7.41%) | 26 (9.09%) | |
2014 | 9 (11.11%) | 21 (7.34%) | |
2015 | 16 (19.75%) | 54 (18.88%) | |
2016 | 20 (24.69%) | 67 (23.43%) | |
2017 | 20 (24.69%) | 73 (25.52%) | |
HER2 | 0.98 | ||
Negative | 37 (45.68%) | 131 (45.8%) | |
Positive | 44 (54.32%) | 155 (54.2%) | |
ER | 0.38 | ||
Negative | 51 (62.96%) | 195 (68.18%) | |
Positive | 30 (37.04%) | 91 (31.82%) | |
PR | 0.28 | ||
Negative | 57 (70.37%) | 218 (76.22%) | |
Positive | 24 (29.63%) | 68 (23.78%) | |
Hormone receptor | 0.56 | ||
Negative | 51 (62.96%) | 190 (66.43%) | |
Positive | 30 (37.04%) | 96 (33.57%) | |
Triple negative | 0.98 | ||
No | 44 (54.32%) | 155 (54.2%) | |
Yes | 37 (45.68%) | 131 (45.8%) | |
CCDMa | 0.53 | ||
2 | 54 (66.67%) | 201 (70.28%) | |
3 | 27 (33.33%) | 85 (29.72%) | |
